1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Pulmonary Arterial Hypertension Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Pulmonary Arterial Hypertension Clinical Trials by Region
2.2.2 Average Enrollment of Pulmonary Arterial Hypertension Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Pulmonary Arterial Hypertension Treatment, 2019

3. Region wise Pulmonary Arterial Hypertension Clinical Trials
3.1 Asia Pacific Pulmonary Arterial Hypertension Clinical Trials by Country
3.2 Europe Pulmonary Arterial Hypertension Clinical Trials by Country
3.3 North America Pulmonary Arterial Hypertension Clinical Trials by Country
3.4 Middle East and Africa Pulmonary Arterial Hypertension Clinical Trials by Country
3.5 South and Central America Pulmonary Arterial Hypertension Clinical Trials by Country

4. Pulmonary Arterial Hypertension Clinical Trial Trends
4.1 Start Year wise Pulmonary Arterial Hypertension Clinical Trials
4.2 Phase wise Pulmonary Arterial Hypertension Clinical Trials
4.3 Trial Status wise Pulmonary Arterial Hypertension Clinical Trials
4.4 Trial Type wise Pulmonary Arterial Hypertension Clinical Trials

5. Pulmonary Arterial Hypertension Average Enrollment Trends
5.1 Average Enrollment in Pulmonary Arterial Hypertension Trials by Year
5.2 Average Enrollment in Pulmonary Arterial Hypertension Trials by Phase
5.3 Average Enrollment in Pulmonary Arterial Hypertension Trials by Status
5.4 Average Enrollment in Pulmonary Arterial Hypertension Trials by Type of Trial

6. Companies Participating in Pulmonary Arterial Hypertension Clinical Trials
6.1 Pulmonary Arterial Hypertension Trials by Sponsor Type
6.2 Pulmonary Arterial Hypertension Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Pulmonary Arterial Hypertension Trials- Phase 1
7.2 Pulmonary Arterial Hypertension Trials- Phase 2
7.3 Pulmonary Arterial Hypertension Trials- Phase 3
7.4 Pulmonary Arterial Hypertension Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Pulmonary Arterial Hypertension Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Figure 5: Europe – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Figure 7: North America – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Figure 9: Pulmonary Arterial Hypertension Clinical Trials by Phase
Figure 10: Pulmonary Arterial Hypertension Clinical Trials by Trial Status
Figure 11: Pulmonary Arterial Hypertension Clinical Trials by Type
Figure 12: Pulmonary Arterial Hypertension Clinical Trials by Sponsor Type
Figure 13: Pulmonary Arterial Hypertension Clinical Trials by Leading Sponsors
Figure 14: Pulmonary Arterial Hypertension Average Enrollment by Phase
Figure 15: Pulmonary Arterial Hypertension Average Enrollment by Trial Status
Figure 16: Pulmonary Arterial Hypertension Average Enrollment by Type
Figure 17: Pulmonary Arterial Hypertension- Average Enrolment by Type of Sponsors
Figure 18: Pulmonary Arterial Hypertension- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Pulmonary Arterial Hypertension Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Table 5: Europe – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Table 7: North America – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Pulmonary Arterial Hypertension Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Pulmonary Arterial Hypertension Average Enrollment by Phase
Table 15: Pulmonary Arterial Hypertension Average Enrollment by Trial Status
Table 16: Pulmonary Arterial Hypertension Average Enrollment by Type
Table 17: Pulmonary Arterial Hypertension- Average Enrolment by Type of Sponsors
Table 18: Pulmonary Arterial Hypertension- Enrolment by Leading Sponsors

Companies mentioned
Arena Pharmaceuticals Inc, Bayer AG, Eli Lilly and Co, Gilead Sciences Inc, GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Pfizer Inc, Pharmaceutical Product Development LLC, United Therapeutics Corp